Business Wire

bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress

Share

bluebird bio, Inc. (Nasdaq: BLUE) announced today that new data from its investigational gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) will be presented during the 24th European Hematology Association (EHA) Congress in Amsterdam, the Netherlands, June 13-16.

bluebird bio will present data from its clinical studies of LentiGlobin™ gene therapy for TDT including updated results up to 54 months from the long-term follow-up period of the completed Phase 1/2 Northstar (HGB-204) study. The company will also present new data from the ongoing Phase 3 Northstar-2 (HGB-207) study in patients who do not have a β00 genotype and from the ongoing Phase 3 Northstar-3 (HGB-212) study in patients who have β00 genotype or an IVS-I-110 mutation.

New data from the company’s Phase 1/2 HGB-206 study of LentiGlobin gene therapy for SCD will include additional patients treated in the study and updated data for those previously reported.

Oral Presentations: Transfusion-Dependent β-Thalassemia

Results from the Phase 3 Northstar-3 Study Evaluating LentiGlobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassaemia and a β 0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene (HGB-212)
Presenting Author: Andreas Kulozik, M.D., Ph.D., University Hospital Heidelberg, Heidelberg, Germany
Date & Time: Friday, June 14, 2019, 11:30 – 11:45 a.m. CEST (5:30 – 5:45 a.m. EDT)

Clinical Outcomes of LentiGlobin Gene Therapy for Transfusion-Dependent β-Thalassaemia (TDT) Following Completion of the Northstar (HGB-204) Study
Presenting Author: Mark Walters, M.D., Benioff Children’s Hospital, Oakland, Calif., U.S.
Date & Time: Friday, June 14, 2019, 11:45 a.m. – 12:00 p.m. CEST (5:45 – 6:00 a.m. EDT)

Safety and Efficacy of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassaemia and Non-β 0 0 Genotypes in the Phase 3 Northstar-2 Study (HGB-207)
Presenting Author: Franco Locatelli, M.D., Ph.D. University of Pavia, Pavia, Lombardy, Italy
Date & Time: Sunday, June 16, 2019, 8:00 – 8:15 a.m. CEST (2:00 – 2:15 a.m. EDT)

Oral Presentation: Sickle Cell Disease

Updated Results from the HGB-206 Study in Patients with Severe Sickle Cell Disease Treated Under a Revised Protocol with LentiGlobin Gene Therapy Using Plerixafor-Mobilised Haematopoietic Stem Cells (HGB-206)
Presenting Author: Julie Kanter, M.D., Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Ala., U.S.
Date & Time: Sunday, June 16, 2019, 8:15 – 8:30 a.m. CEST (2:15 – 2:30 a.m. EDT)

Abstracts outlining bluebird bio’s accepted data at EHA have been made available on the EHA conference website.

Investor Event & Webcast Information

bluebird bio will host a conference call and live webcast at 8:00 a.m. EDT Friday, June 14, 2019. To access the webcast, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com/. A replay of the webcast will be available on the bluebird bio website for 90 days following the call.

About LentiGlobin for Transfusion-Dependent β-Thalassemia

In March 2019, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization for LentiGlobin gene therapy for TDT, which if approved will be commercialized as ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β00 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. ZYNTEGLO adds functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once a patient has the βA-T87Q-globin gene they have the potential to produce HbAT87Q, which is gene therapy- derived-hemoglobin, at levels that significantly reduce or eliminate the need for transfusions.

Non-serious adverse events (AEs) observed during clinical trials that were attributed to ZYNTEGLO were hot flush, dyspnoea, abdominal pain, pain in extremities and non-cardiac chest pain. One serious adverse event (SAE) of thrombocytopenia was considered possibly related to ZYNTEGLO.

Additional AEs observed in clinical studies were consistent with the known side effects of HSC collection and bone marrow ablation with busulfan including SAEs of veno-occlusive disease.

ZYNTEGLO continues to be evaluated in the ongoing Phase 3 Northstar-2 and Northstar-3 studies and the long-term follow-up study LTF-303. If approved, ZYNTEGLO will be the first gene therapy to treat TDT.

About LentiGlobin for Sickle Cell Disease

LentiGlobin for sickle cell disease is an investigational gene therapy being studied as a potential treatment to address the underlying genetic cause of SCD. bluebird bio’s clinical development program for LentiGlobin for SCD includes the ongoing Phase 1/2 HGB-206 study.

bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-303) for people who have participated in bluebird bio-sponsored clinical studies of LentiGlobin for TDT and LentiGlobin for SCD. For more information visit: https://www.bluebirdbio.com/medical-professionals/our-clinical-trials/.

The European Medicines Association (EMA) granted Priority Medicines (PRIME) eligibility and Orphan Medicinal Product designation to LentiGlobin for the treatment of TDT. LentiGlobin for TDT was also part of the EMA’s Adaptive Pathways pilot program, which is part of the EMA’s effort to improve timely access for patients to new medicines.

The U.S. Food and Drug Administration granted Orphan Drug status and Breakthrough Therapy designation to LentiGlobin for TDT; as well as Orphan Drug status and Regenerative Medicine Advanced Therapy designation for LentiGlobin for the treatment of SCD.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbioLinkedInInstagram and YouTube.

ZYNTEGLO and LentiGlobin are trademarks of bluebird bio.

The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that our MAA submitted for LentiGlobin for TDT may not be approved by the European Commission when expected, or at all; the risk that the efficacy and safety results from our prior and ongoing clinical trials of LentiGlobin for TDT will not continue or be repeated in our ongoing or planned clinical trials of LentiGlobin for TDT; the risk that the current or planned clinical trials of LentiGlobin for TDT will be insufficient to support regulatory submissions or marketing approval in the US and EU; the risk that the production of Hb A-T87Q may not be sustained over extended periods of time; and the risk that we may not secure adequate pricing or reimbursement to support continued development or commercialization of LentiGlobin for TDT following regulatory approval. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Contact information

bluebird bio
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

or

Media:
Catherine Falcetti, 339-499-9436
cfalcetti@bluebirdbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Delta-Q Technologies Announces Its New RQ350 Battery Charger for Electric Vehicles and Machines27.5.2020 23:51:00 EESTPress release

Today, Delta-Q Technologies (Delta-Q) introduces its latest sealed charger with the RQ350 for electric vehicles and industrial machines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005918/en/ The RQ350 is an expansion of Delta-Q's RQ Series offering OEMs a charging solution for lower power applications. (Photo: Business Wire) Having found significant market success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels of product reliability, improving machine runtimes. “The RQ350 is a response to our customers’ needs in multiple application segments,” says Lloyd Gomm, VP of Business Development. “Our customers have asked us to bring our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the

City of Austin Partners with NTT to Accelerate Smart City Technologies27.5.2020 23:00:00 EESTPress release

The City of Austin and NTT Corporation (NTT) today announced their intention to partner on an Accelerate Smart pilot project that will use new technologies to analyze traffic patterns, ease congestion and support community planning in Austin. NTT’s Accelerate Smart data platform, as well as modular data center infrastructure for edge deployments, will monitor traffic-related issues downtown using Internet of Things (IoT) devices deployed at the intersections of Cesar Chavez Street and Trinity Street and Neches Street and 8th Street. The smart city project will collect traffic-related and mobility data through vehicle counting and classification, as well as wrong way vehicle occurrences, to provide real-time notifications and better inform how to implement appropriate solutions to fit traffic patterns. “We are piloting NTT because these solutions have the potential to help Austin digitally transform how people move safely through the city. By better understanding the data and causal eff

Monument Re Completes Acquisition of GreyCastle Holdings Ltd and Its Subsidiaries27.5.2020 20:54:00 EESTPress release

Monument Re announced today that it has completed the acquisition of GreyCastle Holdings Ltd. (‘GreyCastle’) and its subsidiaries, which include GreyCastle Life Reinsurance (SAC) Ltd. and GreyCastle Services Ltd., following receipt of regulatory approval from the Bermuda Monetary Authority. About GreyCastle GreyCastle was founded in 2014 by a group of institutional investors to reinsure a block of XL Life Reinsurance life and annuity liabilities of approximately USD4bn. About Monument Re Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios. Monument Re is subject to Group Supervision by the Bermuda Monet

Morgan Stanley Sustainable Signals: Asset Owners See Sustainability as Core to Future of Investing27.5.2020 16:18:00 EESTPress release

A majority of asset owners globally actively integrate ESG factors into their investment process, according to a new survey published today by the Morgan Stanley Institute for Sustainable Investing and Morgan Stanley Investment Management. The new survey polled 110 public and corporate pensions, endowments, foundations, sovereign wealth entities, insurance companies and other large asset owners worldwide, 92% of which had total assets over $1 billion. The survey gathered insights about trends, motivations, challenges and implementation approaches in sustainable investing. This work builds on the Institute’s extensive body of research tracking sustainable investing trends over the last six years through its Sustainable Signals survey series focused on individual investors, asset owners and asset managers. “These results provide an additional proof point that sustainable investing has become table stakes,” said Audrey Choi, Chief Sustainability Officer and CEO of the Institute for Sustai

Sisvel Announces the First Licensees of Its Video Coding Licensing Platform27.5.2020 16:00:00 EESTPress release

Sisvel International S.A. (“Sisvel”) today announced that Mitsubishi Electric Corporation (“Mitsubishi Electric”) has entered into a patent license agreement for both Sisvel’s VP9 and AV1 Licensing Programs. “As a company with a long tradition in research and development in the video coding technologies, it goes without saying that we respect patent positions held by other innovators and that we take a license under the patents offered by Sisvel’s Video Coding Licensing Platform implemented in our products,” says Mr. Yoshimichi Shishido, Senior General manager of Corporate Licensing Division at Mitsubishi Electric. “We have the utmost respect for Mitsubishi Electric’s position and welcome them as the first licensee of our patent pools. We believe this represents a strong signal to the market and we expect that other respectful implementers will follow Mitsubishi Electric’s example,” says Mattia Fogliacco, President of Sisvel International S.A.. Likewise, Sisvel has also granted a licen

Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications27.5.2020 16:00:00 EESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has reduced software issue resolution times by 23% using its new patent pending Rimini Street Artificial Intelligence Support Applications (AI Applications), and that to date the AI Applications have won two awards for innovation and achievement in customer service. The new AI Applications are a result of Rimini Street’s continued investment in optimizing support processes and ensuring global service delivery outcomes at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005073/en/ Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications (Graphic: Business Wire) Delivering a Better Client Experience Through Artificial Intelligence The Rimini Street A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom